Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Karl Griswold
Dartmouth College, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stealth Biologics, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Griswold is the Chief Executive Officer of Stealth Biologics, LLC, a company formed in September 2013 to commercialize certain techniques developed in the lab, including those developed and evaluated as part of this R21 award. He also owns (b)(4) of the company. Given Prof. Griswold's role as PI in this project, his financial interest in Stealth Biologics could significantly and directly affect the design, conduct, and reporting of the research.
Engineer bifunctional antibacterial enzymes for treatment of S. aureus infections
Narrative: Methicillin-resistant Staphylococcus aureus is responsible for approximately half of all US deaths caused by drug-resistant bacterial infections, and this pathogen exerts a massive burden on the healthcare system. Lytic enzymes represent a promising new option for combatting drug-resistant S. aureus, and this proposal seeks to generate high performance, hetero bifunctional, lytic enzyme therapies that integrate two complementary antibacterial biocatalysts into a single, synergistic molecular entity. These designer enzymes could be powerful therapeutics for MRSA and other drug-resistant staph infections.
Filed on June 28, 2016.
Tell us what you know about Karl Griswold's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.